TABLE 2.
The number of events and crude event rates per 100 person-years of outcomes.
| VKA | NOAC | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | |
|---|---|---|---|---|---|---|
| Outcome | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) | Events (per 100 PY) |
| Effectiveness | ||||||
| Stroke or systemic embolism | 1,660 (3.27) | 5,720 (2.10) | 909 (2.03) | 2,467 (2.06) | 1952 (2.16) | 392 (2.34) |
| Stroke | 1,201 (2.35) | 4,905 (1.80) | 778 (1.74) | 2,114 (1.76) | 1700 (1.88) | 313 (1.86) |
| Ischemic stroke | 843 (1.64) | 3,052 (1.11) | 542 (1.20) | 1,310 (1.08) | 1,015 (1.11) | 185 (1.10) |
| Systemic embolism | 498 (0.97) | 952 (0.34) | 161 (0.35) | 406 (0.33) | 294 (0.32) | 91 (0.54) |
| All-cause mortality | 4,264 (8.19) | 20,589 (7.44) | 2,687 (5.89) | 8,688 (7.12) | 7,850 (8.52) | 1,364 (8.06) |
| Myocardial infarction | 497 (0.96) | 2,392 (0.87) | 347 (0.76) | 948 (0.78) | 878 (0.96) | 219 (1.30) |
| Safety | ||||||
| MB/CRNMB | 4,604 (9.57) | 21,397 (8.30) | 2,956 (6.90) | 9,475 (8.40) | 6,981 (8.10) | 1985 (12.40) |
| Major bleeding | 2,686 (5.39) | 12,030 (4.51) | 1800 (4.09) | 5,609 (4.80) | 3,616 (4.04) | 1,005 (6.08) |
| CRNMB | 2,464 (4.93) | 11,705 (4.40) | 1,479 (3.34) | 4,943 (4.22) | 4,102 (4.63) | 1,181 (7.23) |
| Intracranial hemorrhage | 791 (1.55) | 3,011 (1.10) | 476 (1.06) | 1,443 (1.20) | 915 (1.00) | 177 (1.05) |
| Gastrointestinal bleeding | 1,170 (2.28) | 6,483 (2.38) | 1,002 (2.23) | 3,094 (2.59) | 1806 (1.99) | 581 (3.48) |
| Upper gastrointestinal bleeding | 584 (1.13) | 3,161 (1.15) | 461 (1.02) | 1,440 (1.19) | 971 (1.06) | 289 (1.72) |
| Lower gastrointestinal bleeding | 755 (1.47) | 4,091 (1.50) | 638 (1.41) | 2062 (1.71) | 1,047 (1.15) | 344 (2.05) |
| Urogenital bleeding | 681 (1.32) | 4,061 (1.49) | 563 (1.25) | 1825 (1.52) | 1,300 (1.43) | 373 (2.23) |
| Bleeding from other sites | 2,789 (5.60) | 11,490 (4.30) | 1,435 (3.23) | 4,872 (4.14) | 4,018 (4.53) | 1,165 (7.12) |
CRNMB: clinically relevant non-major bleeding; MB: major bleeding; NOAC: non-vitamin K antagonist oral anticoagulant; PY: person-year; VKA: vitamin K antagonist.